Original article by Sarah-Jane Tasker
The Australian – Page: 19 : 29-Aug-17
CSL has announced that it will spend $US91 million ($A114 million) on the purchase of US-based biotechnology company Calimmune. CSL executive Andrew Nash says the purchase of Calimmune gives it access to skills and technologies in the area of gene and cell-based therapies that it does not currently have. He said that CSL has had its eye on Calimmune, which has operations in both the US and Australia, for about a year.
CSL LIMITED – ASX CSL, CALIMMUNE INCORPORATED